PEOPLE - Xtent makes appointment:
This article was originally published in Clinica
Drug-eluting stent developer Xtent (Menlo Park, California) has appointed Michael Eagle to its board of directors. Mr Eagle, who has over 30 years experience in the life-sciences industry, was most recently vice-president of manufacturing at Eli Lilly, a post he held for eight years. He is on the board of several companies, including: Favrille (biopharma, chairman); Radiant Medical (endovascular therapeutic cooling); Siegel-Robert (industrial manufacturing); Somaxon Pharmaceutical; and Micrus Endovascular (cerebrovascular implants and disposables).
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.